ReviewFrontiers in genetics2023
Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma.
Review in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Management of intracranial undifferentiated pleomorphic sarcoma: a systematic review.Neurosurgical review · 2026Pooled it
- Oral and Maxillofacial Low-Grade Myofibroblastic Sarcoma: A Systematic Review.Head and neck pathology · 2025Pooled it
- Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review.Clinical case reports · 2026Article
- Radiotherapy Response Prediction in Myxofibrosarcomas and Undifferentiated Soft Tissue Sarcomas Using DNA Methylation and Copy Number Profiling.International journal of surgical pathology · 2026Article
- Undifferentiated Pleomorphic Sarcoma Mimicking a Refractory Thigh Abscess in a Young Adult: A Diagnostic Pitfall.Cureus · 2026Article
- Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity.Oncology letters · 2026Article
- Misdiagnosed undifferentiated pleomorphic sarcoma of the right lower leg mimicking atypical fibroxanthoma: a case report and literature review.Frontiers in oncology · 2026Article
- ASO Author Reflections: Advancing Prognostics in Oncology: Developing a Machine Learning Model for Predicting 2-Year and 5-Year Survival Rates in Patients with Undifferentiated Pleomorphic Sarcoma.Annals of surgical oncology · 2026Article
- Undifferentiated pleomorphic sarcoma as a rare extracolonic manifestation in Lynch syndrome with MLH1 germline mutation: a case report.Frontiers in oncology · 2026Article
- High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma.Cancer biology & therapy · 2025Article
- Clinicopathological and genomic profiling in undifferentiated pleomorphic sarcoma: Small series, clear message.Journal of applied genetics · 2025Article
- Intracranial undifferentiated pleomorphic sarcoma of right frontal lobe: a case report.Discover oncology · 2025Article
- Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?Cancers · 2025Review
- Cancer‑associated fibroblasts in human malignancies, with a particular emphasis on sarcomas (Review).International journal of oncology · 2025Review
- Undifferentiated pleomorphic sarcoma invading thoracic aorta treated by thoracic endovascular aortic repair: a case report.Journal of medical case reports · 2025Article
- Spontaneous Undifferentiated Pleomorphic Sarcoma With Mast Cell Infiltration in a Sprague-Dawley Rat: A Case Report.Veterinary medicine and science · 2025Article
- Primary Cardiac Myxofibrosarcoma of the Left Atrium with Heterologous Elements Mimicking a Cardiac Myxoma.The American journal of case reports · 2025Article
- Case Report: Three-year follow-up of TACE for recurrent undifferentiated pleomorphic sarcoma: sustained local control and no systemic progression.Frontiers in oncology · 2025Article
- Pembrolizumab combined with surgical treatment for spontaneously ruptured undifferentiated pleomorphic sarcoma of the liver: a case report and literature review.Frontiers in immunology · 2025Review
- Malignant sarcomatous transformation of calvarial fibrous dysplasia: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Undifferentiated pleomorphic sarcoma (UPS), once termed as malignant fibrous histiocytoma, has always been diagnosed exclusively in clinical practice because it lacks any defined resemblance to normal mesenchymal tissue. Although myxofibrosarcoma (MFS) has been separated from UPS due to its fibroblastic differentiation with myxoid stroma, UPS and MFS are still identified as a sarcoma group in terms of molecular landscapes. In this review article, we will describe the associated genes and signaling pathways involved in the process of sarcoma genesis and make a summary of conventional management, targeted therapy, immunotherapy, and some novel potential treatments of UPS/MFS. With the progressive advancements in medical technology and a better understanding about the pathogenic mechanism of UPS/MFS in the coming decades, new lights will be shed on the successful management of UPS/MFS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.